Literature DB >> 2114241

Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.

E Ciccarelli1, E Ghigo, C Miola, G Gandini, E E Muller, F Camanni.   

Abstract

The long-term follow-up (greater than or equal to 4 years) of clinical, hormonal and radiological aspects in 22 'cured' prolactinoma patients after adenomectomy was studied. Dynamic secretion of PRL and TSH was also evaluated, in order to identify the persistence of any underlying abnormality of hypothalamic pituitary control and to predict relapses. A relapse into hyperprolactinaemia was shown in 36% of patients 5-90 months (mean 46) after surgery. This was accompanied by reappearance of clinical symptoms but not by the radiological demonstration of the adenoma in any patients. A significant PRL rise after domperidone, a dopaminergic antagonist drug, was shown in cured patients after surgery (mean +/- SEM peak, 2977 +/- 645 mU/l) but this was markedly lower than that observed in control subjects (5732 +/- 440 mU/l). In fact, normal PRL increments were shown in only 6/16 (37%) patients. TSH hyper-responsiveness to domperidone normalized in only 46% of patients. Similar PRL responses to those obtained with domperidone were shown when a TRH test was given. A relapse into hyperprolactinaemia was observed in six of ten (60%) non-responders to domperidone and in four of seven (57%) non-responders to TRH, whereas six normal responders to domperidone and TRH had not relapsed at that time. Plasma PRL levels during pregnancy showed increments lower than those observed in normal pregnant women only in domperidone and TRH non-responder patients. These results indicate that a relapse into hyperprolactinaemia and a blunted PRL rise during pregnancy were present only in patients with persistently reduced PRL response to dynamic tests.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114241     DOI: 10.1111/j.1365-2265.1990.tb00901.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Endoscopic endonasal surgery for recurrent pituitary tumors: technical challenges to the surgical approach.

Authors:  Bobby A Tajudeen; Jagmeet Mundi; Jeffrey D Suh; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-13

2.  Advances in diagnosing and managing pituitary adenomas.

Authors:  M H Samuels
Journal:  West J Med       Date:  1995-04

3.  The effect of MR contrast medium dose on pituitary gland enhancement, microlesion enhancement and pituitary gland-to-lesion contrast conspicuity.

Authors:  Walter S Bartynski; John F Boardman; Stephen Z Grahovac
Journal:  Neuroradiology       Date:  2006-05-03       Impact factor: 2.804

Review 4.  Diagnosis and drug therapy of prolactinoma.

Authors:  E Ciccarelli; F Camanni
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

5.  Transsphenoidal surgery for pituitary adenoma: indications and outcomes.

Authors:  Tina Dusek; Ante Melada; Josip Paladino; Darko Kastelan
Journal:  Croat Med J       Date:  2012-12       Impact factor: 1.351

Review 6.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

7.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.